

NCTN Adolescent and Young Adult (AYA) Cancer Trials Portfolio (Open as of 6/15/2026)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease

Osteosarcoma (Pulmonary mets)

AOST2031

Osteosarcoma (High Grade)

AOST2032

Classical Hodgkin Lymphoma

AHOD2131

Invasive Breast Carcinoma
(HR+/HER2-)

NRG-BR009 (OFSET)*^

Germ Cell Tumors

AGCT1531

AGCT1532

Precursor B-Lymphoblastic Leukemia
(B-Cell ALL)

A041501*

Adrenocortical Carcinoma

A092204

Low-grade Astrocytoma

A072301

Recurrent Disease

Precursor B-Lymphoblastic Leukemia
(B-Cell ALL)

AALL1821

Osteosarcoma (Pulmonary mets)

AOST2031

Precursor T-Lymphoblastic Leukemia/
Lymphoma (T-Cell ALL/LBL) - MRD

EA9213

Adrenocortical Carcinoma

A092204

Legend by Disease Types

Green =
Osteosarcoma

Orange =
Hodgkin
Lymphoma

Purple =
Breast

Yellow =
Germ Cell
Tumors

Blue =
B-Cell
ALL

Light Green =
Adrenocortical
Carcinoma

Light Gray =
Low-grade
Astrocytoma

Light Blue =
T-Cell ALL /
T-Cell LBL

Note: * NRG-BR009 and A041501: Age 18 years and older; ^ NRG-BR009: COG is not directly participating.

NCTN Adolescent and Young Adult (AYA) Cancer Trials (Open as of 6/15/2026)

| Protocol Number | Phase | Protocol Title |
|------------------|--------|---|
| A041501 | III | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL |
| A072301 | III | Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas |
| A092204 | II | A Phase II Study of Cabozantinib in Combination with Cemiplimab (REGN2810) (Cabo-Cemiplimab (REGN-2810)) Versus Cabozantinib Alone in Adolescents and Adults with Advanced Adrenocortical Cancer |
| AALL1821 | II | A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years Old with First Relapse |
| AGCT1531 | III | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors |
| AGCT1532 | III | A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors |
| AHOD2131 | III | A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma |
| AOST2031 | III | A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma |
| AOST2032 | II/III | A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma |
| EA9213 | II | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL) |
| NRG-BR009 | III | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET) |

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>